Full Breakdown
Trump Plans to Fire FDA Commissioner Marty Makary Amid Agency Turmoil
5/9/2026, 10:24:31 PM
Core Event: Trump’s Reported Decision to Dismiss Makary
President Donald Trump has reportedly signed off on a plan to remove Dr. Marty Makary as Food and Drug Administration commissioner. The move, reported by multiple outlets on May 8 2026, follows weeks of conflict over flavored-vape approvals, the abortion-pill mifepristone, and rare-disease drug rejections.
Background & Context: Makary’s Tenure and Agency Strains
Makary, a former Johns Hopkins surgeon, was confirmed in March 2025. He pushed a food-dye phase-out, tightened COVID-shot reviews, and supported the “Make America Healthy Again” agenda. The FDA rejected UniQure’s Huntington’s-disease gene therapy, paused Moderna’s flu-vaccine application, and delayed a promised mifepristone safety review, drawing criticism from conservatives and biotech firms.
Key Figures & Groups
President Donald Trump; FDA commissioner Dr. Marty Makary; Kush Desai; Robert F. Kennedy Jr.; Marjorie Dannenfelser; John Crowley; Kelly Ryerson; Richard Pazdur.
Timeline
- March 2025 – Makary confirmed as FDA commissioner.
- February 2026 – Delayed approval of fruit-flavored vapes from Glas.
- May 8 2026 – WSJ reports Trump’s frustration; FDA authorizes blueberry and mango flavors; outlets say Trump signed off on Makary’s removal.
Data & Statistics
The FDA rejects about 20 % of drug applications. UniQure’s stock rose 13 % after news of Makary’s possible exit. A Pro-Life America poll shows one-third of GOP voters are less enthusiastic if mifepristone restrictions are not tightened.
Why It Matters / Impact
A leadership change could reshape FDA policy on flavored nicotine products, rare-disease therapies, and abortion-pill regulation before the 2026 midterms, and signal broader instability in the administration’s health-agency hierarchy.
Official Statements & Responses
Desai praised the administration’s experience; Trump said he knew nothing about any firing; Makary asserted that effective drugs will be approved.
Criticism & Opposition
Pro-Life America president Marjorie Dannenfelser called Makary’s tenure “a five-alarm crisis” and urged dismissal. BIO president John Crowley condemned his personnel cuts as “indiscriminate.” MAHA advocate Kelly Ryerson called the firing “corporate-funded attacks.”
Conflicting Reports & Gaps
Some outlets say Trump signed the firing order; others note his denial and that the plan could change. Reports differ on whether Makary deliberately delayed the mifepristone safety review or postponed it for electoral timing.
Verbatim Quotes
- “President Trump has assembled the most experienced and talented administration in history, an administration that continues to focus on delivering more historic victories for the American people,” — Kush Desai, White House spokesman
- “I've been reading about it, but I know nothing about it.” — Donald Trump, press briefing
- “This is a five-alarm crisis for the pro-life movement and for the GOP,” — Marjorie Dannenfelser, Pro-Life America
- “wall between the commissioner’s office and the review staff has been breached” — Richard Pazdur, former CDR director
What’s Next
HHS officials are weighing deputy commissioners Kyle Diamantas, Grace Graham, and Lowell Zeta as acting heads, while a permanent nominee would need Senate confirmation. The decision could shape FDA actions on vaping, rare-disease drugs, and mifepristone policy before the November elections.
